About: Data of Italian Cancer Centers from two regions with high incidence of Sars CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Data of Italian Cancer Centers from two regions with high incidence of Sars CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Data of Italian Cancer Centers from two regions with high incidence of Sars CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
Creator	Andrea, Agostini De Pas, Tommaso Fava, Paolo Fierro, Maria Giugliano, Federica Jemos, Costantino Marco, Rubatto Pala, Laura Quaglino, Pietro Queirolo, Paola Salè, Emanuela Saponara, Maristella Methodologyinvestigation, M
Source	Elsevier; PMC
abstract	Background: Patients with cancer are presumed to have a higher risk to contract SARS-CoV-2 infection, because of their immunosuppressed status. The impact and course of COVID-19 infection in cancer patients receiving immunotherapy remains unknown. Objectives: To evaluate the safety of the management of patients with advanced melanoma treated with immunotherapy in two Cancer Centers located in areas of Italy with a high incidence of COVID-19 infections. Methods: We retrospectively analyzed data from January 1 to April 30, 2020 on patients with locally advanced and metastatic melanoma receiving immunotherapy at either Istituto Europeo di Oncologia (IEO) or Città della Salute e della Scienza University Hospital (CSSUH). Results: One-hundred and sixty nine patients with stage III and IV melanoma were treated with an immunotherapy regimen at either IEO or CSSUH. One-hundred and four patients continued treatment without interruption or delay, while 49 patients had a treatment delay. The main reasons for treatment delay were older age (median age of the group of patients with or without treatment-delay, respectively 60 and 69 years, p-value <0.001) and/or presence of comorbidities (percentage of patients with at least one comorbidity respectively 81% and 62%, in patients with or without treatment delay, p-value=0.001). One-hundred and twelve patients had at least one thoracic CT scan performed and radiological findings suspicious for COVID-19 were observed in only seven cases (4%). Fifteen patients (9%) developed symptoms potentially related to COVID-19; naso-pharingeal swabs were collected in nine patients and only one was positive for SARS-CoV-2. Conclusions The incidence of symptomatic COVID-19 infection observed in our cohort of patients with advanced malignant melanoma treated with immunotherapy appears meaningfully lower as compared with that reported in the overall population in Italy as well as in patients affected by solid tumors. We conclude that in patients with locally advanced and metastatic melanoma, immunotherapy can be safely continued without delay in the majority of cases, reserving precautionary delay only for the most frail patients.
has issue date	2020-08-07(xsd:dateTime)
bibo:doi	10.1053/j.seminoncol.2020.07.010
has license	no-cc
sha1sum (hex)	4905e5c3dc367c39fb25c15e4d5374f6d32ecc66
schema:url	https://doi.org/10.1053/j.seminoncol.2020.07.010
resource representing a document's title	Data of Italian Cancer Centers from two regions with high incidence of Sars CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
has PubMed Central identifier	PMC7413095
schema:publication	Semin Oncol
resource representing a document's body	covid:4905e5c3dc367c39fb25c15e4d5374f6d32ecc66#body_text
is schema:about of	named entity 'advanced' named entity 'Data' named entity 'patients' named entity 'infection' named entity 'INFECTION' named entity 'INCIDENCE' named entity 'melanoma' named entity 'melanoma' named entity 'Sars' named entity 'advanced' named entity 'regions' named entity 'locally' named entity 'locally advanced' named entity 'immunotherapy' named entity 'infection' named entity 'locally advanced' named entity 'COVID-19' named entity 'infection' named entity 'immunotherapy' named entity 'infection' named entity 'immunotherapy' named entity 'fever' named entity 'hydroxychloroquine' named entity 'higher risk' named entity 'comorbidity' named entity 'solid tumors' named entity 'health concern' named entity 'immunosuppressed' named entity 'Funding source' named entity 'COVID' named entity 'cough' named entity 'COVID-19 pandemic' named entity 'solid tumors' named entity 'IEO' named entity 'SARS-CoV-2' named entity 'melanoma' named entity 'anosmia' named entity 'viral infection' named entity 'infection' named entity 'outpatient' named entity 'infection' named entity 'COVID' named entity 'Lombardy' named entity 'melanoma' named entity 'Italy' named entity 'immunotherapy' named entity 'COVID' named entity 'immunotherapy' named entity 'immunotherapy' named entity 'stage III' named entity 'metastatic melanoma' named entity 'p-value' named entity 'complete response' named entity 'IEO' named entity 'tumor' named entity 'Piedmont' named entity 'stage IV' named entity 'COVID-19 infection' named entity 'IEO' named entity 'malignant melanoma' named entity 'stage III' named entity 'comorbidity' named entity 'radiotherapy' named entity 'comorbidities' named entity 'chemotherapy' named entity 'pembrolizumab' named entity 'oncologic' named entity 'higher risk' named entity 'Lombardy' named entity 'dyspnea' named entity 'Piedmont'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software